Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131(6):803–820. https://doi.org/10.1007/s00401-016-1545-1

Article  PubMed  Google Scholar 

Ostrom QT, Cioffi G, Gittleman H et al (2019) CBTRUS Statistical Report: primary brain and other Central Nervous System tumors diagnosed in the United States in 2012–2016. Neuro Oncol 21(Suppl 5):v1–v100. https://doi.org/10.1093/neuonc/noz150

Article  PubMed  PubMed Central  Google Scholar 

Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. https://doi.org/10.1056/NEJMoa043330

Article  CAS  PubMed  Google Scholar 

Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466. https://doi.org/10.1016/S1470-2045(09)70025-7

Article  CAS  PubMed  Google Scholar 

Mauer M, Stupp R, Taphoorn MJ et al (2007) The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC brain Tumour and Radiation Oncology groups, and NCIC Clinical Trials Group study. Br J Cancer 97(3):302–307. https://doi.org/10.1038/sj.bjc.6603876

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bottomley A, Vanvoorden V, Flechtner H, Therasse P, EORTC Quality of Life Group EORTC Data Center (2003) The challenges and achievements involved in implementing quality of life research in cancer clinical trials. Eur J Cancer 39(3):275–285. https://doi.org/10.1016/s0959-8049(02)00729-3

Article  CAS  PubMed  Google Scholar 

Perry JR, Laperriere N, O’Callaghan CJ et al (2017) Short-course Radiation plus Temozolomide in Elderly patients with Glioblastoma. N Engl J Med 376(11):1027–1037. https://doi.org/10.1056/NEJMoa1611977

Article  CAS  PubMed  Google Scholar 

Pollom EL, Sborov KD, Soltys SG, Asch SM, Sudore RL, Aslakson RA (2018) Advance Care Planning needs in patients with Glioblastoma Undergoing Radiotherapy. J Pain Symptom Manage 56(6):e6–e8. https://doi.org/10.1016/j.jpainsymman.2018.08.021

Article  PubMed  PubMed Central  Google Scholar 

Hendren S, Chin N, Fisher S et al (2011) Patients’ barriers to receipt of cancer care, and factors associated with needing more assistance from a patient navigator. J Natl Med Assoc 103(8):701–710. https://doi.org/10.1016/s0027-9684(15)30409-0

Article  PubMed  Google Scholar 

Williams M, Treasure P, Greenberg D, Brodbelt A, Collins P (2016) Surgeon volume and 30 day mortality for brain tumours in England. Br J Cancer 115(11):1379–1382. https://doi.org/10.1038/bjc.2016.317

Article  PubMed  PubMed Central  Google Scholar 

Barker FG 2nd, Curry WT Jr, Carter BS (2005) Surgery for primary supratentorial brain tumors in the United States, 1988 to 2000: the effect of provider caseload and centralization of care. Neuro Oncol 7(1):49–63. https://doi.org/10.1215/S1152851704000146

Article  PubMed  PubMed Central  Google Scholar 

Walker EV, Davis FG (2019) CBTR founding affiliates. Malignant primary brain and other central nervous system tumors diagnosed in Canada from 2009 to 2013. Neuro Oncol 21(3):360–369. https://doi.org/10.1093/neuonc/noy195

Article  PubMed  PubMed Central  Google Scholar 

Weerasinghe A, Smith CR, Majpruz V et al (2018) Validity of administrative databases in comparison to medical charts for breast Cancer Treatment Data. J Cancer Epidemiol 2018:9218595. https://doi.org/10.1155/2018/9218595

Article  PubMed  PubMed Central  Google Scholar 

Statistics Canada Tables 17-10-0134-01 Population estimates, July 1, by health region and peer group, 2018 boundaries. https://doi.org/10.25318/1710013401-eng

Voisin MR, Sasikumar S, Mansouri A, Zadeh G (2021) Incidence and prevalence of primary malignant brain tumours in Canada from 1992 to 2017: an epidemiologic study. CMAJ Open 9(4):E973–E979. https://doi.org/10.9778/cmajo.20200295

Article  PubMed  PubMed Central  Google Scholar 

Marenco-Hillembrand L, Wijesekera O, Suarez-Meade P et al (2020) Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis. J Neurooncol 147(2):297–307. https://doi.org/10.1007/s11060-020-03451-6

Article  PubMed  Google Scholar 

Raphael MJ, Siemens DR, Booth CM (2019) Would regionalization of systemic Cancer Therapy improve the quality of Cancer Care? J Oncol Pract 15(7):349–356. https://doi.org/10.1200/JOP.18.00671

Article  PubMed  Google Scholar 

Lopez Ramos C, Brandel MG, Steinberg JA et al (2019) The impact of traveling distance and hospital volume on post-surgical outcomes for patients with glioblastoma. J Neurooncol 141(1):159–166. https://doi.org/10.1007/s11060-018-03022-w

Article  PubMed  Google Scholar 

Longo CJ, Fitch M, Deber RB, Williams AP (2006) Financial and family burden associated with cancer treatment in Ontario, Canada. Support Care Cancer 14(11):1077–1085. https://doi.org/10.1007/s00520-006-0088-8

Article  PubMed  Google Scholar 

Smets T, Lawson TM, Grandin C, Jankovski A, Raftopoulos C (2013) Immediate post-operative MRI suggestive of the site and timing of glioblastoma recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol 23(6):1467–1477. https://doi.org/10.1007/s00330-012-2762-1

Article  PubMed  Google Scholar 

Tamimi AF, Juweid M Epidemiology and outcome of Glioblastoma. In: De Vleeschouwer S (ed) Glioblastoma. Brisbane (AU): Codon; September 27, 2017

Holdhoff M, Ye X, Blakeley JO et al (2012) Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas. J Neurooncol 110(2):279–285. https://doi.org/10.1007/s11060-012-0968-3

Article  CAS  PubMed  Google Scholar 

Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897):1807–1812. https://doi.org/10.1126/science.1164382

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chakrabarti I, Cockburn M, Cozen W, Wang YP, Preston-Martin S (2005) A population-based description of glioblastoma multiforme in Los Angeles County, 1974–1999. Cancer 104(12):2798–2806. https://doi.org/10.1002/cncr.21539

Article  PubMed  Google Scholar 

Mackillop WJ, Zhang-Salomons J, Groome PA, Paszat L, Holowaty E (1997) Socioeconomic status and cancer survival in Ontario. J Clin Oncol 15(4):1680–1689. https://doi.org/10.1200/JCO.1997.15.4.1680

Article  CAS  PubMed  Google Scholar 

Porter AB, Lachance DH, Johnson DR (2015) Socioeconomic status and glioblastoma risk: a population-based analysis. Cancer Causes Control 26(2):179–185. https://doi.org/10.1007/s10552-014-0496-x

Article  PubMed  Google Scholar 

Kasl RA, Brinson PR, Chambless LB (2016) Socioeconomic status does not affect prognosis in patients with glioblastoma multiforme. Surg Neurol Int.;7(Suppl 11):S282-S290. Published 2016 May 6. https://doi.org/10.4103/2152-7806.181985

Gorey KM, Luginaah IN, Bartfay E et al (2011) Effects of socioeconomic status on colon cancer treatment accessibility and survival in Toronto, Ontario, and San Francisco, California, 1996–2006. Am J Public Health 101(1):112–119. https://doi.org/10.2105/AJPH.2009.173112

Article  PubMed  PubMed Central  Google Scholar 

Kovic B, Xie F (2015) Economic evaluation of Bevacizumab for the First-Line treatment of newly diagnosed Glioblastoma Multiforme. J Clin Oncol 33(20):2296–2302. https://doi.org/10.1200/JCO.2014.59.7245

Article  PubMed  Google Scholar 

Henriksson R, Asklund T, Poulsen HS (2011) Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. J Neurooncol 104(3):639–646. https://doi.org/10.1007/s11060-011-0565-x

Article  CAS  PubMed  PubMed Central